Clinical Trial Update: Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial is investigating ex vivo renal perfusion with SYN002 to prevent Cytomegalovirus transmission in kidney transplant recipients; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• SYN002

Snippet

Sponsor: University Health Network, Toronto | Conditions: Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient | EARLY_Phase 1 | Status: NOT_YET_RECRUITING